Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Pharmacol. Mar 9, 2015; 4(1): 117-143
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.117
Drug therapy for Parkinson’s disease: An update
Omar ME Abdel-Salam
Omar ME Abdel-Salam, Department of Toxicology and Narcotics, Medical Division, National Research Centre, Cairo 12311, Egypt
Author contributions: Abdel-Salam OME solely contributed to this paper.
Conflict-of-interest: The author declare that there are no conflicting of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Omar ME Abdel-Salam, MD, PhD, Department of Toxicology and Narcotics, Medical Division, National Research Centre, Tahrir Street, Cairo 12311, Egypt. omasalam@hotmail.com
Telephone: +2-02-33335996 Fax: +2-02-33370931
Received: June 22, 2014
Peer-review started: June 23, 2014
First decision: July 10, 2014
Revised: January 26, 2015
Accepted: February 9, 2015
Article in press: February 11, 2015
Published online: March 9, 2015
Core Tip

Core tip: Parkinson’s disease (PD) is a neurodegenerative disorder for which currently there is no cure. The advent of many therapies such as levodopa (L-dopa), dopamine-receptor-agonists, monoamine oxidase type B inhibitors, and catechol-O-methyltransferase inhibitors helped much to ease the life and to improve health-related quality of life of PD patients. Among these drugs, L-dopa remains the most effective agent for treatment of motor symptoms in PD. These agents provide symptomatic relief for motor symptoms but there is no evidence that these could alter the natural course of the disease and prevent the progressive dopaminergic neuronal loss. There is, however, encouraging data that suggest a benefit from iron chelation therapy with deferiprone and from the use of antioxidants or mitochondrial function enhancers in preventing or delaying the progression of PD.